3 Ticagrelor has a beneficial synergistic relationship with endothelial vasodilators in patients with coronary disease

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

Endogenous endothelial vasodilators and ticagrelor both vasodilate and inhibit platelets. This study evaluated a potential mechanistic interaction between ticagrelor and endothelial vasodilators in patients with stable coronary disease.

Methods

Participants were assessed at baseline and after 3 days of ticagrelor. Blood samples were incubated with nitric oxide (GSNO) donor or prostacyclin (PGI2) and then maximally activated. Using flow cytometry, P-selectin, VASP phosphorylation (-P) and platelet leukocyte aggregate (PLA) associated fluorescence were quantified as measures of platelet activation. EndoPAT measured endothelial function (reactive hyperaemic index (RHI)).

Results

Sixty-three patients were included. There was a synergistic relationship between ticagrelor and both vasodilators (GSNO and PGI2) (Figure). VASP-P, as evidence of signalling, was significantly increased in platelets post ticagrelor. PLA results were consistent and showed a greater response to prostacyclin after ticagrelor. RHI increased post ticagrelor (1.91 to 2.04 p=0.049). The magnitude of RHI increase positively correlated to the extent of platelet inhibition by ticagrelor (p=0.014).

Conclusion

P2Y12 inhibition by ticagrelor enhances the antiplatelet effects of endothelial vasodilators and endothelial function. The extent of endothelial improvement can predict the anti-platelet response to ticagrelor.

Related Topics

    loading  Loading Related Articles